OptumHealth Opioid MDL Ruling: Polster Keeps UnitedHealth Affiliates in PBM Bellwethers

The OptumHealth opioid MDL ruling, issued on October 15, 2026 by U.S. District Judge Dan Aaron Polster of the Northern District of Ohio, holds that three out-of-state UnitedHealth Group affiliates (OptumHealth Care Solutions LLC, OptumHealth Holdings LLC and Optum Health Networks Inc.) must stay in two pharmacy benefit manager bellwether cases and defend federal racketeering and related state-law claims in Cleveland. It is the first significant ruling in the PBM phase of In re National Prescription Opiate Litigation, MDL No. 2804, since the Sixth Circuit on October 2 granted mandamus and struck Judge Polster's order allowing roughly 800 plaintiffs to add claims against OptumRx and Express Scripts.

Taken together, the two rulings narrow the PBM docket and keep its defendants in place. The court of appeals cut back how many plaintiffs may sue the PBMs inside the Multidistrict Litigation (MDL). Two weeks later the district court made sure the Optum corporate family cannot leave the cases that remain by arguing it was never subject to suit in Ohio. This article explains both decisions, the RICO jurisdiction doctrine behind the second one, and what each means for the plaintiffs, the defendants and the bellwether calendar.

What Judge Polster decided about OptumHealth in the opioid MDL

Judge Polster denied the OptumHealth entities' motion to dismiss for lack of personal jurisdiction. According to Law360 and LawCommentary, the three companies, none of them based in Ohio, can be required to answer civil RICO claims and related state-law claims in the two bellwether cases to which they had earlier been restored as defendants. Mealey's, reporting the order on October 19, describes the court as finding personal jurisdiction under the RICO statute's venue-and-process provision, plus "pendent claim personal jurisdiction" over the state-law counts.

The defendants also relied on a recent Sixth Circuit decision. Law360 reports that the court found that decision did not change its jurisdiction over the related state-law claims. The public reporting does not name the appellate decision, and this article does not guess. What the ruling plainly does is keep the full Optum family available to plaintiffs in the PBM bellwethers at a time when other parts of that track have just been cut back.

The order decides where the companies can be sued. It does not decide whether they did anything wrong. It makes no finding that any OptumHealth entity contributed to opioid misuse or is liable for harm, and the companies dispute the allegations.

Is OptumHealth the same company as OptumRx?

No. OptumRx is UnitedHealth Group's pharmacy benefit manager. It negotiates with drug manufacturers, builds formularies and runs mail-order pharmacy operations, and it is the Optum entity named most often in PBM opioid litigation. OptumHealth is the group's health care delivery arm. The three entities in the October 15 order are OptumHealth Care Solutions LLC, OptumHealth Holdings LLC and Optum Health Networks Inc.

The distinction matters here. According to LawCommentary, OptumRx had already accepted the Ohio court's jurisdiction, so the jurisdictional fight concerned only the OptumHealth affiliates. Plaintiffs want those affiliates in the case because the complaints allege a single enterprise across the Optum family, and because a judgment or settlement that binds only the PBM subsidiary may not reach every entity that, on the plaintiffs' theory, shared in the conduct. Defendants wanted them out for the opposite reason. Each affiliate that stays adds to the discovery burden and to the settlement exposure.

How can an Ohio court have personal jurisdiction over out-of-state Optum companies?

Through RICO's nationwide service provision, a "home" claim, and the doctrine of pendent personal jurisdiction. The steps are as follows.

Step one: the RICO anchor. Civil RICO has its own venue-and-process section, 18 U.S.C. § 1965. Subsection (b) allows a court hearing a RICO action against a defendant properly before it to summon other parties "residing in any other district" when "the ends of justice require" it. The Sixth Circuit reads that provision narrowly. In Peters Broadcast Engineering, Inc. v. 24 Capital, LLC, No. 21-3849, decided July 13, 2022, the court adopted the majority "forum state" approach: § 1965(b) governs nationwide service, and at least one defendant must have minimum contacts with the forum before other defendants can be brought in. The Fourth and Eleventh Circuits read § 1965(d) more broadly, so the circuits are split.

Step two: the "ends of justice" test. The Sixth Circuit tightened the test again on June 16, 2026. In Hall v. Trivest Partners L.P., Nos. 25-1278/1538, Judge Kethledge, joined by Judge Bush, reversed a Michigan district court that had exercised RICO jurisdiction over nine Florida corporations with no Michigan contacts because litigating in Michigan would be no less convenient than litigating in Florida. The majority held that convenience alone does not satisfy the "ends of justice" requirement. Judge Clay dissented. After Hall, a district court in this circuit needs a reason stronger than convenience before it reaches defendants that have no contacts of their own with the forum.

Step three: pendent personal jurisdiction. Once a court properly has personal jurisdiction over a defendant on a federal claim with a nationwide-service provision, it may also hear state-law claims against that defendant that arise from the same nucleus of operative fact, even if those state-law claims could not have been brought in the forum on their own. That is the "pendent claim personal jurisdiction" Mealey's describes. The doctrine has limits. It depends on a valid federal anchor claim, and the Sixth Circuit in Peters Broadcast affirmed dismissal of both the RICO and state-law claims when the anchor failed.

Applied here. The October 15 order treats the RICO claims as a valid basis for jurisdiction over the OptumHealth affiliates and the state-law claims as riding along with them. The full text of the order is not yet publicly available, so the exact § 1965(b) reasoning cannot be quoted. But the result shows that, on these allegations, Judge Polster found the federal anchor sound and saw no reason in recent appellate authority to separate the state-law counts from it.

What did the Sixth Circuit decide in In re OptumRx?

On October 2, 2026 a unanimous Sixth Circuit panel of Judges Danny Boggs, Richard Griffin and Stephanie Davis granted the petition for a writ of mandamus in In re OptumRx, Inc., No. 26-3780, and vacated Judge Polster's July 27, 2026 order. That order had allowed roughly 800 plaintiffs already in MDL No. 2804 to amend their complaints to add claims against OptumRx and Express Scripts. According to Bloomberg Law, the panel said the district court "clearly abused its discretion" in letting plaintiffs add the new defendants about two years after the scheduled deadline.

The legal error was procedural. Rule 16(b)(4) of the Federal Rules of Civil Procedure allows a scheduling order to be modified only for good cause, and the core of good cause is the moving party's diligence. Judge Polster had resolved the amendments on a single omnibus motion brought by the Plaintiffs' Executive Committee and found good cause across the board. As Mealey's and Bloomberg Law describe it, the panel held that he had to examine each amended complaint and decide whether that particular plaintiff had been diligent.

This is the second time the Sixth Circuit has corrected the opioid MDL on late amendments. In In re National Prescription Opiate Litigation, 956 F.3d 838 (6th Cir. 2020), decided April 15, 2020, the court granted mandamus to pharmacy defendants and ordered amendments stricken that two Ohio counties had filed about nineteen months after the deadline. Its best-known line was that there is no "MDL exception" to the Federal Rules. The 2026 panel applied that principle to the PBM track. Sullivan & Cromwell, counsel for OptumRx with Alston & Bird, says the vacated order had increased the number of cases against its client tenfold.

Why the OptumHealth opioid MDL ruling and the mandamus point in different directions

The two rulings answer different questions, which is why one is a defense win and the other a plaintiffs' win.

The mandamus concerns which plaintiffs may sue. It strikes a mass amendment that would have brought hundreds of new public-entity plaintiffs into the PBM fight through a single order. The October 15 ruling concerns which defendants must answer. It rejects an attempt to shrink the defendant roster in cases that were already properly pleaded. Nothing in the mandamus opinion, as reported, questions the court's power over defendants in the existing bellwethers, and the October 15 order expressly found that recent Sixth Circuit authority did not undercut its jurisdiction.

The practical result is a smaller PBM docket with every Optum defendant still in it. For settlement purposes, the PBMs now face fewer claimants in the MDL, but they cannot use corporate structure to wall off affiliates from the cases that do go forward. The comparison table below sets the two decisions side by side.

	In re OptumRx, No. 26-3780 (6th Cir.)	October 15 OptumHealth order (N.D. Ohio)
Date	October 2, 2026	October 15, 2026
Decision-maker	Boggs, Griffin, Davis, JJ. (unanimous)	Judge Dan Aaron Polster
Question	May ~800 plaintiffs add OptumRx and Express Scripts by omnibus amendment?	Must out-of-state OptumHealth entities defend claims in Ohio?
Rule or statute	Fed. R. Civ. P. 16(b)(4) good cause	18 U.S.C. § 1965(b); pendent personal jurisdiction
Outcome	Mandamus granted; July 27, 2026 order vacated	Motion to dismiss denied; entities stay in two bellwethers
Who it helps	PBM defendants	Plaintiffs

What happens to the 800 PBM opioid claims now?

The amendments fall away, but the claims are not decided on the merits. Each affected plaintiff must either seek leave again with an individualized showing of diligence under Rule 16(b)(4) or bring a separate action against the PBMs. The reported opinion does not spell out the remand instructions, so the precise procedure on remand is not yet public.

Either path is costly. An individualized motion has to explain why that county or city did not sue the PBMs by the original deadline. Some will have a good answer, for example later-discovered evidence about formulary or rebate conduct. Many will not. A fresh action brings in the Statute of Limitations, which has already ended at least one major municipal PBM case: the City of Boston's suit against PBMs was dismissed as time-barred under a three-year limitations period, and the First Circuit affirmed. Any public entity that relied on the July 27 order instead of filing on its own should assume defendants will raise the same argument.

Removal is a further consideration. As this site reported in September, four federal courts of appeals, including the Sixth Circuit in Commonwealth of Kentucky v. Express Scripts, Inc., No. 25-5866, have accepted federal officer jurisdiction over PBM claims. A plaintiff that refiles in state court should expect removal and a tag-along transfer to the MDL, which brings it back before the court whose amendment order was just vacated.

Which opioid MDL bellwether cases involve PBMs, and when could one be tried?

Judge Polster opened a PBM bellwether track limited to the Optum and Express Scripts defendant families. Court filings on the MDL website identify the bellwether plaintiffs as including County of Webb, Texas (transferred into the MDL on February 12, 2018), City of Rochester, New York, City of Independence, Missouri, and Lincoln County. In a March 2024 stipulation the Optum defendants preserved their personal jurisdiction defenses, and that is the defense the October 15 order has now rejected for the OptumHealth entities in two of those cases. Public reporting does not say which two.

No Bellwether Trial against a PBM has produced a verdict in the MDL. The nearest firm trial date is in state court. Jefferson County, Missouri's case against Express Scripts and Optum Rx is set for a jury trial in March 2027. Other fronts are also growing. On October 1, 2026 Arizona Attorney General Kris Mayes filed a consumer fraud suit in Maricopa County Superior Court alleging that the two PBMs took confidential manufacturer payments, including from Purdue Pharma, in exchange for preferred OxyContin coverage and relaxed prior authorization controls. Optum has denied the allegations.

Date	Event
Feb. 12, 2018	County of Webb, Texas, transferred into MDL No. 2804
Apr. 15, 2020	Sixth Circuit grants mandamus striking late pharmacy amendments, 956 F.3d 838
July 13, 2022	Peters Broadcast adopts the forum-state reading of RICO § 1965(b)
Mar. 2024	Stipulation lists PBM bellwether cases; Optum preserves personal jurisdiction defenses
Aug. 2024	Judge Polster declines, for now, to dismiss municipalities' claims against Express Scripts and OptumRx
June 16, 2026	Hall v. Trivest: convenience does not meet RICO's "ends of justice" test
July 27, 2026	Judge Polster allows ~800 plaintiffs to add OptumRx and Express Scripts
Aug. 27, 2026	PBMs docket mandamus petition, No. 26-3780
Sept. 18, 2026	Sixth Circuit holds Kentucky's PBM opioid suit belongs in federal court
Oct. 1, 2026	Arizona sues Express Scripts and Optum in Maricopa County Superior Court
Oct. 2, 2026	Sixth Circuit grants mandamus and vacates the July 27 order
Oct. 15, 2026	OptumHealth entities' jurisdiction motion denied; they remain in two bellwethers
Mar. 2027	Jefferson County, Missouri, state-court trial against Express Scripts and Optum Rx

What it means for plaintiffs, PBM defendants and MDL practitioners

For public-entity plaintiffs and their counsel. The bellwether plaintiffs now have a full Optum defendant roster, which supports enterprise-wide discovery and a settlement that binds every affiliate. Plaintiffs among the roughly 800 whose amendments were vacated should be preparing individualized diligence records and running limitations analyses now. The Boston dismissal shows what happens when a public entity waits.

For PBM defense teams. The mandamus grant shows that procedural challenges to aggregation can succeed in the Sixth Circuit. The October 15 order shows the limit of that strategy. Corporate separateness is a weak jurisdictional defense when the complaint pleads a RICO enterprise and at least one family member is properly before the court. Arguments under Hall v. Trivest are strongest for affiliates whose connection to the alleged scheme is thin, not for those pleaded as part of it.

For MDL practitioners generally. Under Rule 16.1, in force since December 1, 2025, a transferee court can manage pleading and amendment at scale, but the Sixth Circuit has now said twice that case management does not replace the case-by-case findings the Federal Rules require. Leadership counsel who plan to add a defendant track by omnibus motion should build an individualized good-cause record from the start.

For litigation funders and portfolio holders. Funded public-entity PBM claims now carry two separate risks. One is whether a given plaintiff stays in the MDL at all. The other is the limitations exposure that comes with refiling. A bellwether in which the defendants' jurisdictional defenses have been rejected is worth more than one in which they are still open.

Frequently asked questions

What did Judge Polster decide about OptumHealth in the opioid MDL?

On October 15, 2026 he denied the motion to dismiss filed by OptumHealth Care Solutions LLC, OptumHealth Holdings LLC and Optum Health Networks Inc., holding that the Northern District of Ohio has personal jurisdiction over them for the RICO claims and, through pendent personal jurisdiction, for the related state-law claims in two PBM bellwether cases.

Is OptumHealth the same company as OptumRx?

No. OptumRx is UnitedHealth Group's pharmacy benefit manager and had already accepted the Ohio court's jurisdiction. OptumHealth is the group's health care delivery arm, and the October 15 order concerned three OptumHealth entities.

What did the Sixth Circuit decide in In re OptumRx?

On October 2, 2026 the Sixth Circuit granted mandamus and vacated the July 27, 2026 order allowing roughly 800 plaintiffs to add claims against OptumRx and Express Scripts. It held that the district court clearly abused its discretion by finding good cause on an omnibus basis, about two years after the deadline, instead of plaintiff by plaintiff.

What happens to the 800 PBM opioid claims after the Sixth Circuit ruling?

The amendments are vacated but the claims are not decided. Each plaintiff must make an individualized Rule 16(b)(4) diligence showing or file a separate action, and a separate action may face statute of limitations defenses like the one that ended the City of Boston's PBM suit.

Does the OptumHealth ruling mean Optum is liable for the opioid crisis?

No. The ruling decides only that the OptumHealth entities can be sued in Ohio. It makes no finding on the merits, and the companies deny the allegations.

Has any PBM opioid case gone to trial?

Not yet. No PBM bellwether in MDL No. 2804 has reached a verdict, and the nearest firm trial setting is Jefferson County, Missouri's state-court case against Express Scripts and Optum Rx, scheduled for March 2027.